se ha leído el artículo
array:25 [ "pii" => "S1578219020302122" "issn" => "15782190" "doi" => "10.1016/j.adengl.2019.01.023" "estado" => "S300" "fechaPublicacion" => "2020-09-01" "aid" => "2370" "copyright" => "AEDV" "copyrightAnyo" => "2020" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:609-10" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0001731020301678" "issn" => "00017310" "doi" => "10.1016/j.ad.2019.01.016" "estado" => "S300" "fechaPublicacion" => "2020-09-01" "aid" => "2370" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:609-10" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Foro del residente</span>" "titulo" => "FR - Prevención farmacológica del cáncer cutáneo no-melanoma en pacientes de alto riesgo" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "609" "paginaFinal" => "610" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF - Pharmacological Prevention of Nonmelanoma Skin Cancer in High-Risk Patients" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "X. Bosch-Amate, D. Morgado-Carrasco, N. Martínez" "autores" => array:3 [ 0 => array:2 [ "nombre" => "X." "apellidos" => "Bosch-Amate" ] 1 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 2 => array:2 [ "nombre" => "N." "apellidos" => "Martínez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219020302122" "doi" => "10.1016/j.adengl.2019.01.023" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020302122?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020301678?idApp=UINPBA000044" "url" => "/00017310/0000011100000007/v1_202009110631/S0001731020301678/v1_202009110631/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219020302134" "issn" => "15782190" "doi" => "10.1016/j.adengl.2020.08.009" "estado" => "S300" "fechaPublicacion" => "2020-09-01" "aid" => "2376" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2020;111:611" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Images in Dermatology</span>" "titulo" => "«Before applying the next dose, peel the white film off the lesion»" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "611" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "«Antes de la siguiente aplicación, retira la película blanca»" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 757 "Ancho" => 1007 "Tamanyo" => 145114 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Appearance of patient's forehead on entering the consulting room.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. López Gómez, Z. Ezsol Lendvai, M.I. de la Hera Matute" "autores" => array:3 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "López Gómez" ] 1 => array:2 [ "nombre" => "Z." "apellidos" => "Ezsol Lendvai" ] 2 => array:2 [ "nombre" => "M.I." "apellidos" => "de la Hera Matute" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731020301733" "doi" => "10.1016/j.ad.2018.08.019" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020301733?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020302134?idApp=UINPBA000044" "url" => "/15782190/0000011100000007/v1_202009190930/S1578219020302134/v1_202009190930/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S157821902030216X" "issn" => "15782190" "doi" => "10.1016/j.adengl.2020.08.012" "estado" => "S300" "fechaPublicacion" => "2020-09-01" "aid" => "2391" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2020;111:605-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Brief Comunication</span>" "titulo" => "Photodynamic Therapy for Necrobiosis Lipoidica: Successful Treatment in a Series of 4 cases" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "605" "paginaFinal" => "608" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento de la necrobiosis lipoídica con terapia fotodinámica convencional: serie de 4 casos tratados con éxito" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1542 "Ancho" => 2181 "Tamanyo" => 512887 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Case 1. A 21-year-old woman with DM1 and necrobiosis lipoidica with a long time since onset (72 months). Appearance of the lesions at the start (A and B) and after completing treatment with conventional PDT with MAL (C and D). gr1.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Bernia, B. Llombart, B. Bancalari, A. Diago, C. Serra-Guillén" "autores" => array:5 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Bernia" ] 1 => array:2 [ "nombre" => "B." "apellidos" => "Llombart" ] 2 => array:2 [ "nombre" => "B." "apellidos" => "Bancalari" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Diago" ] 4 => array:2 [ "nombre" => "C." "apellidos" => "Serra-Guillén" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731020301885" "doi" => "10.1016/j.ad.2019.01.022" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731020301885?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S157821902030216X?idApp=UINPBA000044" "url" => "/15782190/0000011100000007/v1_202009190930/S157821902030216X/v1_202009190930/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Resident's Forum</span>" "titulo" => "RF - Pharmacological Prevention of Nonmelanoma Skin Cancer in High-Risk Patients" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "609" "paginaFinal" => "610" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "X. Bosch-Amate, D. Morgado-Carrasco, N. Martínez" "autores" => array:3 [ 0 => array:4 [ "nombre" => "X." "apellidos" => "Bosch-Amate" "email" => array:1 [ 0 => "xavi_bosch92@hotmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 2 => array:2 [ "nombre" => "N." "apellidos" => "Martínez" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Servicio de Dermatología, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR - Prevención farmacológica del cáncer cutáneo no-melanoma en pacientes de alto riesgo" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Nonmelanoma skin cancer (NMSC) is the most common neoplasia in humans. It includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Its main risk factors are accumulated exposure to sunlight, immunosuppression, and infection with the beta human papillomavirus. The use of topical sunscreen is frequently indicated in secondary prevention. In recent years, new evidence supports the use of some drugs as chemoprophylactics (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0010" class="elsevierStylePara elsevierViewall">A randomized double-blind clinical trial in 932 high-risk patients (98% Caucasian males, with a mean age of 71 years) was recently published. Chemoprevention was studied using a cycle of 5% topical fluorouracil (every 12<span class="elsevierStyleHsp" style=""></span>h for 4 weeks) (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>468) versus placebo (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>464) on the appearance of NMSC of the face and ears with surgical indication. In the first year after treatment a lower number of SCC was detected (1% versus 4%) (risk reduction of 75% [95% CI, 35%–91%] [<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.002]). No differences were found in BCC (10% versus 11%), although the number of Mohs surgeries in the first year dropped. After 4 years of follow-up, no differences were found in the number of SCC or BCC between the 2 groups (39% versus 38%). In terms of adverse effects, 92% of the group receiving fluorouracil presented erythema (21% described it as severe), but 85% would use the treatment again if necessary.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> These results suggest that a cycle of topical fluorouracil would be useful in secondary prevention of SCC for a year. It remains to be demonstrated whether an annual cycle of 5% topical fluorouracil is an effective long-term strategy. We must remember that 5-fluoracil is not sold in Spain and must be formulated. This may limit its potential use in Spain.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Previously, a phase-III randomized, double-blind, placebo-controlled clinical trial in 386 high-risk patients had demonstrated the efficacy of oral nicotinamide (500<span class="elsevierStyleHsp" style=""></span>mg/12<span class="elsevierStyleHsp" style=""></span>h of vitamin B3) as chemoprevention for NMSC. In the 12 months that the nicotinamide was used, the number of NMSC per person was reduced (1.8 versus 2.4), with a risk reduction of 23% (95% CI, 4%–38%) (<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.02), and the drug was well tolerated. This protective effect was lost 6 months after the treatment ended.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Oral retinoids have been shown to be of use in chemoprevention of NMSC while they are being used. In a randomized, placebo-controlled clinical trial (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2297), the risk of SCC was lower among those who received 25,000<span class="elsevierStyleHsp" style=""></span>IU/d of retinol (vitamin A) (hazard ratio, 0.74 [95% CI, 0.56–0.99] [<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>.04]).<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> Other smaller studies have shown the efficacy of isotretinoin and oral acitretin in reducing the risk of NMSC, but with greater toxicity.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">2,4</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Other oral drugs studied include capecitabin, celecoxib, and ibuprofen, but greater evidence is required for their use to be recommended. Most of the above-mentioned treatments have demonstrated efficacy in preventing SCC but not BCC. This may be explained by their different etiologies, including the fact that UV radiation damage and viral infection are not as important in BCC. In terms of treatment of NMSC precursor lesions, different topical agents have been shown to be effective, such as ingenol mebutate, imiquimod, and diclofenac. Photodynamic therapy is also highly effective in the treatment of these lesions.</p><p id="par0030" class="elsevierStylePara elsevierViewall">In solid-organ transplant and immunosuppressed patients, it is important to reduce immunosuppression to the minimum effective dose and to replace calcineurin inhibitors (cyclosporin and tacrolimus) with mTOR inhibitors (sirolimus or everolimus). The use of sirolimus has been associated with a significant reduction in the risk of NMSC.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">5</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Different pharmacological options exist for patients with a high risk of developing NMSC, such as 5% topical fluorouracil, retinoids, and oral nicotinamide to reduce this risk and the associated morbidity and mortality.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1273668" "palabras" => array:5 [ 0 => "Basal cell carcinoma" 1 => "Squamous cell carcinoma" 2 => "Skin cancer" 3 => "Prevention" 4 => "5-Fluorouracil" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "⋆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Bosch-Amate X, Morgado-Carrasco D, Martínez N. FR - Prevención farmacológica del cáncer cutáneo no-melanoma en pacientes de alto riesgo. Actas Dermosifiliogr. 2020;111:609–610.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Abbreviations: SCC indicates squamous cell carcinoma; NMSC, nonmelanoma skin cancer; RCT, randomized clinical trial; AK, actinic keratosis.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Drug \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Route of Administration \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Dosage \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Evidence in Favor \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5-Fluorouracil \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical, 5% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Twice daily for 4 weeks (an annual cycle?) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RCT in high-risk patients (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>932). Reduced rate of SCC in the 1st year<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Retinol \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">25,000<span class="elsevierStyleHsp" style=""></span>IU/day for 5 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RCT in high-risk patients (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>2297). Reduced risk of SCC while treatment lasted<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">3</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Acitretin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30<span class="elsevierStyleHsp" style=""></span>mg/day for 6 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RCT in kidney-transplant patients (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>44). Reduced risk of NMSC while treatment lasted<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">4</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nicotinamide \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Oral \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">500<span class="elsevierStyleHsp" style=""></span>mg twice daily for a year \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RCT in high-risk patients (n<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>386). Reduced risk of NMSC and AK while treatment lasted<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">2</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2383104.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Drugs Used in Secondary Prevention of Nonmelanoma Skin Cancer.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemoprevention of basal and squamous cell carcinoma with a single course of fluorouracil, 5%, cream: a randomized clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.A. Weinstock" 1 => "S.S. Thwin" 2 => "J.A. Siegel" 3 => "K. Marcolivio" 4 => "A.D. Means" 5 => "N.F. Leader" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamadermatol.2017.3631" "Revista" => array:6 [ "tituloSerie" => "JAMA Dermatol" "fecha" => "2018" "volumen" => "154" "paginaInicial" => "167" "paginaFinal" => "174" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29299592" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.C. Chen" 1 => "A.J. Martin" 2 => "B. Choy" 3 => "P. Fernández-Peñas" 4 => "R.A. Dalziell" 5 => "C.A. McKenzie" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1506197" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2015" "volumen" => "373" "paginaInicial" => "1618" "paginaFinal" => "1626" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26488693" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T.E. Moon" 1 => "N. Levine" 2 => "B. Cartmel" 3 => "J.L. Bangert" 4 => "S. Rodney" 5 => "Q. Dong" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Cancer Epidemiol Biomark Prev" "fecha" => "1997" "volumen" => "6" "paginaInicial" => "949" "paginaFinal" => "956" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.N. Bavinck" 1 => "L.M. Tieben" 2 => "F.J. Woude" 3 => "A.M. Tegzess" 4 => "J. Hermans" 5 => "J. ter Schegget" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.1995.13.8.1933" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "1995" "volumen" => "13" "paginaInicial" => "1933" "paginaFinal" => "1938" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/7636533" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Sirolimus effects on cancer incidence after kidney transplantation: a meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "E.L. Yanik" 1 => "K. Siddiqui" 2 => "E.A. Engels" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/cam4.487" "Revista" => array:6 [ "tituloSerie" => "Cancer Med" "fecha" => "2015" "volumen" => "4" "paginaInicial" => "1448" "paginaFinal" => "1459" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26108799" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000011100000007/v1_202009190930/S1578219020302122/v1_202009190930/en/main.assets" "Apartado" => array:4 [ "identificador" => "34945" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Resident's Forum" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000011100000007/v1_202009190930/S1578219020302122/v1_202009190930/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219020302122?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 6 | 9 | 15 |
2024 Octubre | 70 | 50 | 120 |
2024 Septiembre | 69 | 22 | 91 |
2024 Agosto | 81 | 59 | 140 |
2024 Julio | 54 | 25 | 79 |
2024 Junio | 68 | 30 | 98 |
2024 Mayo | 61 | 26 | 87 |
2024 Abril | 66 | 19 | 85 |
2024 Marzo | 53 | 32 | 85 |
2024 Febrero | 58 | 30 | 88 |
2024 Enero | 39 | 32 | 71 |
2023 Diciembre | 44 | 11 | 55 |
2023 Noviembre | 70 | 32 | 102 |
2023 Octubre | 56 | 29 | 85 |
2023 Septiembre | 45 | 28 | 73 |
2023 Agosto | 30 | 15 | 45 |
2023 Julio | 47 | 32 | 79 |
2023 Junio | 42 | 16 | 58 |
2023 Mayo | 58 | 23 | 81 |
2023 Abril | 42 | 17 | 59 |
2023 Marzo | 68 | 25 | 93 |
2023 Febrero | 42 | 24 | 66 |
2023 Enero | 38 | 23 | 61 |
2022 Diciembre | 37 | 29 | 66 |
2022 Noviembre | 22 | 34 | 56 |
2022 Octubre | 26 | 20 | 46 |
2022 Septiembre | 22 | 32 | 54 |
2022 Agosto | 28 | 41 | 69 |
2022 Julio | 43 | 34 | 77 |
2022 Junio | 31 | 25 | 56 |
2022 Mayo | 42 | 35 | 77 |
2022 Abril | 38 | 25 | 63 |
2022 Marzo | 48 | 46 | 94 |
2022 Febrero | 30 | 21 | 51 |
2022 Enero | 39 | 53 | 92 |
2021 Diciembre | 30 | 44 | 74 |
2021 Noviembre | 36 | 46 | 82 |
2021 Octubre | 63 | 54 | 117 |
2021 Septiembre | 37 | 43 | 80 |
2021 Agosto | 32 | 34 | 66 |
2021 Julio | 23 | 22 | 45 |
2021 Junio | 24 | 26 | 50 |
2021 Mayo | 30 | 45 | 75 |
2021 Abril | 96 | 77 | 173 |
2021 Marzo | 62 | 25 | 87 |
2021 Febrero | 54 | 27 | 81 |
2021 Enero | 36 | 15 | 51 |
2020 Diciembre | 42 | 23 | 65 |
2020 Noviembre | 36 | 21 | 57 |
2020 Octubre | 51 | 17 | 68 |
2020 Septiembre | 52 | 32 | 84 |
2020 Agosto | 24 | 12 | 36 |